News
ORMP
3.960
0.00%
0.000
Weekly Report: what happened at ORMP last week (0518-0522)?
Weekly Report · 4d ago
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Seeking Alpha · 6d ago
Oramed: Q1 Earnings Snapshot
Barchart · 05/19 16:36
Weekly Report: what happened at ORMP last week (0511-0515)?
Weekly Report · 05/18 10:25
Oramed Pharmaceuticals Delays Quarterly SEC Filing
TipRanks · 05/15 23:34
Oramed delays Q1 10-Q filing, cites need to finalize financial statements
PUBT · 05/15 20:10
Lifeward files initial beneficial ownership statement for Oramed Pharmaceuticals stake
PUBT · 05/14 21:20
Weekly Report: what happened at ORMP last week (0504-0508)?
Weekly Report · 05/11 10:22
Weekly Report: what happened at ORMP last week (0427-0501)?
Weekly Report · 05/04 10:20
Weekly Report: what happened at ORMP last week (0420-0424)?
Weekly Report · 04/27 10:23
Weekly Report: what happened at ORMP last week (0413-0417)?
Weekly Report · 04/20 10:18
Weekly Report: what happened at ORMP last week (0406-0410)?
Weekly Report · 04/13 10:22
Weekly Report: what happened at ORMP last week (0330-0403)?
Weekly Report · 04/06 10:23
Oramed Completes Oratech Sale and Strategic Lifeward Financing
TipRanks · 04/01 00:08
Oramed completes Oratech sale to Lifeward for shares, warrants, revenue-sharing payments
Reuters · 03/31 20:22
Weekly Report: what happened at ORMP last week (0323-0327)?
Weekly Report · 03/30 10:23
Oramed FY2025 profit rises to $64.0 million; revenue climbs to $2.0 million
Reuters · 03/26 21:16
Oramed: Q4 Earnings Snapshot
Barchart · 03/26 16:50
Lifeward closes strategic partnership agreement with Oramed
TipRanks · 03/25 20:45
Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals
Benzinga · 03/25 20:17
More
Webull provides a variety of real-time ORMP stock news. You can receive the latest news about Oramed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.